Name

Medroxyprogesterone

Alternate Names

Medroxyprogesterone

Abbreviations

MPA

Category

Hormones and hormonal mechanisms

Subcategory

Hormone

NSC Number

None

Primary Site

breast cancer
Endometrial cancer

Histology

None

Remarks

Medroxyprogesterone has received FDA approval for treatment of advanced and recurrent endometrial cancers. This drug lessens the tumor burden allowing for surgical treatment. If given prior to surgical treatment, code as neo-adjuvant therapy.

In clinical trials for breast cancer and Renal Cell Carcinoma of the kidney.

Coding

This drug should be coded
Glossary